| scholarly article | Q13442814 |
| P50 | author | Kevork M. Peltekian | Q42939206 |
| P2093 | author name string | Ingrid S Sketris | |
| Susan Kirkland | |||
| Ethel Langille Ingram | |||
| Chiranjeev Sanyal | |||
| P2860 | cites work | Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns | Q24234308 |
| Barriers to patient-physician communication about out-of-pocket costs | Q24550529 | ||
| Patient-physician communication about out-of-pocket costs | Q28202715 | ||
| Physician strategies to reduce patients' out-of-pocket prescription costs | Q28242042 | ||
| Physician consideration of patients' out-of-pocket costs in making common clinical decisions | Q28297315 | ||
| A cross-national study of prescription nonadherence due to cost: data from the Joint Canada-United States Survey of Health | Q33257937 | ||
| The impact of pharmacy discharge planning on continuity of care. | Q33555180 | ||
| A new measure of medication affordability | Q33945830 | ||
| Hepatitis C: diagnosis and treatment | Q34022660 | ||
| When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions | Q34132608 | ||
| Why do some patients not cash their prescriptions? | Q34468948 | ||
| Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment. | Q34781593 | ||
| Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. | Q35105731 | ||
| Primary non-compliance with prescribed medication in primary care | Q35189637 | ||
| Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK. | Q36216765 | ||
| A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures | Q36226626 | ||
| What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries | Q36699426 | ||
| Coping with prescription drug cost sharing: knowledge, adherence, and financial burden | Q36741639 | ||
| Effect of copayments on drug use in the presence of annual payment limits. | Q36848926 | ||
| Complementary and alternative medicine use in chronic liver disease patients | Q37061693 | ||
| Complementary and alternative medicine use by patients chronically infected with hepatitis C virus | Q37134227 | ||
| Medication strategies used by Medicare beneficiaries who reach the Part D standard drug-benefit threshold | Q37171578 | ||
| Patients' unvoiced agendas in general practice consultations: qualitative study | Q37330631 | ||
| Challenges in chronic illness management: a qualitative study of Australian pharmacists' perspectives. | Q37772419 | ||
| Drug coverage in Canada: who is at risk? | Q39372698 | ||
| Physicians' opinions about responsibility for patient out-of-pocket costs and formulary prescribing in two Midwestern states | Q39861247 | ||
| Prescription drug samples--does this marketing strategy counteract policies for quality use of medicines? | Q40569029 | ||
| Access to medicines: cost as an influence on the views and behaviour of patients | Q40578666 | ||
| Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic | Q42614732 | ||
| Adverse events associated with prescription drug cost-sharing among poor and elderly persons | Q42644645 | ||
| Unintended consequences of caps on Medicare drug benefits | Q42687029 | ||
| Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity | Q50147877 | ||
| Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. | Q50747988 | ||
| Blurring of the Public/Private Divide: The Canadian Chapter | Q57112196 | ||
| Estimating future hepatitis C morbidity, mortality, and costs in the United States | Q73073538 | ||
| Problems paying out-of-pocket medication costs among older adults with diabetes | Q75346061 | ||
| Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs? | Q80994104 | ||
| The case against excessive cost sharing | Q83153082 | ||
| The impact of prescription charges on asthma patients is uneven and unpredictable: evidence from qualitative interviews | Q83957811 | ||
| P433 | issue | 2 | |
| P921 | main subject | Hepatitis C virus | Q708693 |
| P304 | page(s) | 131-140 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Canadian Journal of Hospital Pharmacy | Q15765960 |
| P1476 | title | Coping strategies used by patients infected with hepatitis C virus who are facing medication costs | |
| P478 | volume | 64 |
| Q56917730 | Influence of healthcare-associated factors on the efficacy of hepatitis C therapy |
| Q36638638 | Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review |
| Q38120496 | Protease inhibitors for hepatitis C: economic implications |
| Q92777890 | Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment |
Search more.